Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2379]

The placebo effect in oncology trials and the criteria for approving drugs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

The placebo effect in oncology trials and the criteria for approving drugs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

ZUMA-7: Axi-cel is superior to standard of care across common prognostic...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

ASH 2022: Multiple myeloma roundup

Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA

ASH 2022: Multiple myeloma roundup ( Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA )

Breast cancer patients who interrupted endocrine therapy to pursue pregnancy...

Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain

Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )

Interruption of endocrine therapy in young breast cancer patients does not...

Dr Ann Partridge - Dana-Farber Cancer Institute, Boston, USA

Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse ( Dr Ann Partridge - Dana-Farber Cancer Institute, Boston, USA )

Genetic profiling identifies patients who can omit radiation therapy after...

Prof Per Karlsson - Sahlgrenska Comprehensive Cancer Centre, Gothenburg, Sweden

Genetic profiling identifies patients who can omit radiation therapy after breast-conserving surgery ( Prof Per Karlsson - Sahlgrenska Comprehensive Cancer Centre, Gothenburg, Sweden )

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival...

Dr Monzr Al Malki - City of Hope, Duarte, USA

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease ( Dr Monzr Al Malki - City of Hope, Duarte, USA )

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA

Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )

Longest follow-up of patients with early breast cancer shows radiotherapy does...

Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK

Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years ( Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK )

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R...

Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma ( Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA )

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients...

Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients having a suboptimal response to ruxolitinib ( Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA )

More from ecancer